Work

Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience

Year: 2018

Type: article

Study design: Observational Study

Source: Clinical Breast Cancer

DOI: 10.1016/j.clbc.2018.07.008

Authors: Rashmi K. Murthy, Akshara S. Raghavendra, Kenneth R. Hess, Takeo Fujii, Bora Lim, Carlos H. Barcenas, Hong Zhang, Mariana Chavez-Mac-Gregor, Elizabeth A. Mittendorf, Jennifer K. Litton, Sharon H. Giordano, Alastair M. Thompson, Vicente Valero, Stacy L. Moulder, Debu Tripathy, Naoto T. Ueno

Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Cancer Institute

Awards: Cancer Center Support Grant, Paul Calabresi Clinical Oncology Award

OpenAlex ID: W2853312207

FWCI: 0.551

Cites: 28

Cited by: 12

Related to: 10